Related Experiment Video
Updated: May 29, 2026
11:29
Surgical Techniques to Optimize Ovarian Reserve during Laparoscopic Cystectomy for Ovarian Endometrioma
Published on: January 22, 2022
Surgery for recurrent ovarian cancer
Florian Heitz1, Andreas du Bois, Christian Kurzeder
1Department of Gynecology & Gynecological Oncology, Kliniken Essen-Mitte, Huyssen-Stiftung/Knappschaft GmbH, Essen, Germany. florian.heitz@gmx.net
Women'S Health (London, England)
|September 2, 2011
Summary
Predicting complete resection in recurrent ovarian cancer is crucial. A validated score identifies patients likely to achieve complete tumor removal, optimizing treatment and avoiding unnecessary surgery.
Area of Science:
- Gynecologic Oncology
- Surgical Oncology
Background:
- Cytoreductive surgery is standard for primary ovarian cancer.
- Its role in recurrent ovarian cancer is debated due to limited prospective data.
- Complete resection of recurrent tumors is associated with improved survival.
Purpose of the Study:
- To discuss recent data on surgery for recurrent ovarian cancer.
- To highlight the importance of predictors for complete resection.
- To emphasize the benefits of including these patients in randomized trials.
Main Methods:
- Review of recent data on recurrent ovarian cancer surgery.
- Discussion of the AGO-DESKTOP II trial.
- Validation of the AGO score for predicting complete resection.
Main Results:
- The AGO score predicts complete resection in recurrent ovarian cancer.
- Patients with ECOG 0, no residual disease, and no ascites have a 76% likelihood of complete resection.
- Identifying predictors helps guide surgical decisions.
Conclusions:
- Complete resection is the goal in recurrent ovarian cancer surgery.
- The AGO score is a valuable tool for predicting complete resection.
- Further randomized trials are needed to optimize treatment for recurrent ovarian cancer.
